Account
Inquiry
QSC Tirzepatide is a novel dual GLP-1 and GIP receptor agonist peptide with significant potential in metabolic disorder research. This synthetic peptide with CAS number 2023788-19-2 has shown promising results in clinical studies related to weight management and glucose control.
The peptide works by simultaneously activating both GLP-1 and GIP receptors, which play crucial roles in glucose metabolism and energy homeostasis. This dual mechanism of action makes QSC Tirzepatide particularly interesting for researchers studying obesity and type 2 diabetes.
Our QSC Tirzepatide is produced under strict GMP conditions with comprehensive quality control measures. Each batch undergoes rigorous testing including HPLC purity analysis, mass spectrometry confirmation, and endotoxin testing to ensure research-grade quality.
Key research applications include: metabolic syndrome studies, weight management mechanisms, glucose homeostasis research, and comparative studies with other GLP-1 receptor agonists.
As with all our peptide products, this material is provided for research use only and not intended for human consumption. Proper handling procedures should be followed in accordance with laboratory safety protocols.
The stability of QSC Tirzepatide has been demonstrated in various research settings, making it suitable for both short-term and long-term studies when stored under recommended conditions.
